文献速递糖尿病

COVID-19大流行对儿童1型糖尿病诊断时糖尿病酮症酸中毒患病率长期趋势的影响:基于13个国家糖尿病登记数据的国际多中心研究

Impact of the COVID-19 pandemic on long-term trends in the prevalence of diabetic ketoacidosis at diagnosis of paediatric type 1 diabetes: an international multicentre study based on data from 13 national diabetes registries.
PubMed 文献 · Lancet Diabetes Endocrinol · 2022-10-03

该国际多中心研究基于13个国家糖尿病登记数据,纳入2006年至2021年诊断的104 290例儿童青少年1型糖尿病患者,比较2020和2021年糖尿病酮症酸中毒患病率与大流行前趋势预测值。结果显示2020年调整患病率39.4%、2021年38.9%,均显著高于预测值32.5%和33.0%(p<0.0001)。防控措施严格度指数每增加10单位,2020年风险比1.037、2021年1.028。

要点

  • 2020年糖尿病酮症酸中毒调整患病率39.4%,显著高于预测值32.5%(p<0.0001)。
  • 2021年糖尿病酮症酸中毒调整患病率38.9%,显著高于预测值33.0%(p<0.0001)。
  • 防控措施严格度指数每增加10单位,2020年风险比1.037、2021年1.028。

核心结论

  • COVID-19大流行期间,儿童1型糖尿病诊断时糖尿病酮症酸中毒患病率较原有上升趋势明显加剧。
  • 该发现强调儿童青少年1型糖尿病需早期及时诊断。

研究设计与样本

  • 国际多中心研究,使用13个国家糖尿病登记数据(澳大利亚、奥地利、捷克、丹麦、德国、意大利、卢森堡、新西兰、挪威、斯洛文尼亚、瑞典、美国科罗拉多、威尔士)。
  • 研究人群为2006年1月1日至2021年12月31日诊断的104 290例6个月至18岁以下儿童青少年1型糖尿病患者。
  • 将2020和2021年观察到的糖尿病酮症酸中毒患病率与基于2006-19年大流行前趋势的预测值比较。
  • 分析糖尿病酮症酸中毒患病率变化与COVID-19大流行严重程度及防控措施的关联,使用全人群超额全因死亡率和牛津COVID-19政府响应追踪系统的严格度指数。

主要发现

  • 2006至2019年诊断87 228例,2020年诊断8209例,2021年诊断8853例。
  • 2006至2019年,87 228例中诊断时糖尿病酮症酸中毒者23 775例(27.3%),总队列糖尿病酮症酸中毒患病率年均增幅1.6%(95%CI 1.3至1.9)。
  • 2020年糖尿病酮症酸中毒调整患病率39.4%(95%CI 34.0至45.6),2021年38.9%(33.6至45.0),均显著高于预测值2020年32.5%(27.8至37.9)和2021年33.0%(28.3至38.5)(两年p<0.0001)。
  • 糖尿病酮症酸中毒患病率与防控措施相关:严格度指数每增加10单位,2020年估计风险比1.037(95%CI 1.024至1.051;p<0.0001),2021年1.028(1.009至1.047;p=0.0033)。
  • 糖尿病酮症酸中毒患病率与超额全因死亡率无显著关联。

临床怎么用

  • 原文结论强调儿童青少年1型糖尿病需早期及时诊断。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: An increased prevalence of diabetic ketoacidosis at diagnosis of type 1 diabetes in children was observed in various diabetes centres worldwide during the COVID-19 pandemic. We aimed to evaluate trends in the prevalence of diabetic ketoacidosis at diagnosis of paediatric type 1 diabetes before and during the COVID-19 pandemic, and to identify potential predictors of changes in diabetic ketoacidosis prevalence during the pandemic. METHODS: For this international multicentre study, we used data from 13 national diabetes registries (Australia, Austria, Czechia, Denmark, Germany, Italy, Luxembourg, New Zealand, Norway, Slovenia, Sweden, USA [Colorado], and Wales). The study population comprised 104 290 children and adolescents aged 6 months to younger than 18 years, who were diagnosed with type 1 diabetes between Jan 1, 2006, and Dec 31, 2021. The observed diabetic ketoacidosis prevalence in 2020 and 2021 was compared to predictions based on trends over the pre-pandemic years 2006-19. Associations between changes in diabetic ketoacidosis prevalence and the severity of the COVID-19 pandemic and containment measures were examined with excess all-cause mortality in the whole population and the Stringency Index from the Oxford COVID-19 Government Response Tracker. FINDINGS: 87 228 children and adolescents were diagnosed with type 1 diabetes between 2006 and 2019, 8209 were diagnosed in 2020, and 8853 were diagnosed in 2021. From 2006 to 2019, diabetic ketoacidosis at diagnosis of type 1 diabetes was present in 23 775 (27·3%) of 87 228 individuals and the mean annual increase in the prevalence of diabetic ketoacidosis in the total cohort from 2006 to 2019 was 1·6% (95% CI 1·3 to 1·9). The adjusted observed prevalence of diabetic ketoacidosis at diagnosis of type 1 diabetes was 39·4% (95% CI 34·0 to 45·6) in 2020 and 38·9% (33·6 to 45·0) in 2021, significantly higher than the predicted prevalence of 32·5% (27·8 to 37·9) for 2020 and 33·0% (28·3 to 38·5) for 2021 (p<0·0001 for both years). The prevalence of diabetic ketoacidosis was associated with the pandemic containment measures, with an estimated risk ratio of 1·037 (95% CI 1·024 to 1·051; p<0·0001) per ten-unit increase in the Stringency Index for 2020 and 1·028 (1·009 to 1·047; p=0·0033) for 2021, but was not significantly associated with excess all-cause mortality. INTERPRETATION: During the COVID-19 pandemic, there was a marked exacerbation of the pre-existing increase in diabetic ketoacidosis prevalence at diagnosis of type 1 diabetes in children. This finding highlights the need for early and timely diagnosis of type 1 diabetes in children and adolescents. FUNDING: German Federal Ministry for Education and Research, German Robert Koch Institute, German Diabetes Association, German Diabetes Foundation, Slovenian Research Agency, Welsh Government, Central Denmark Region, and Swedish Association of Local Authorities and Regions.

来源:Lancet Diabetes Endocrinol,查看原文。版权归原作者所有。

引用

  1. Birkebaek NH, Kamrath C, Grimsmann JM, et al. Impact of the COVID-19 pandemic on long-term trends in the prevalence of diabetic ketoacidosis at diagnosis of paediatric type 1 diabetes: an international multicentre study based on data from 13 national diabetes registries. Lancet Diabetes Endocrinol. 2022. PMID: 36202118. doi:10.1016/S2213-8587(22)00246-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。